Inactief instrument

Andere talen Endologix, Inc.

Aandelen

ELGXQ

US29266S3040

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	05/03
Endologix LLC Announces That Art Taylor Joins Board of Directors	25/01
Endologix LLC Appoints Scott Ward Joins Board of Directors	09/01
Endologix LLC Announces Appointment of Scott Ward as Board of Directors	09/01
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	27/12
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	02/11
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	07-09-23
Endologix LLC Appoints Lucas Buchanan to its Board of Directors	24-08-23
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	18-07-23
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	15-06-23
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	08-06-23
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23-05-23
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	11-11-22
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	03-11-22
Endologix LLC Announces the Elevate	20-10-22
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	10-10-22
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	23-06-22
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA	23-11-21
Endologix Appoints Dr. Matthew Thompson as CEO	16-11-21
Endologix, Inc. Announces Board and Executive Changes	16-11-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Endologix, Inc.

Aandelen

ELGXQ

US29266S3040

Andere talen

Filters